Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Carsten Müller-Tidow Andre Franke Martin Stanulla Timo Gaiser Philip Rosenstiel |
| Publication date | July 5, 2017 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |